Neutralising antibodies targeting PDPN showed inhibition of tumour growth and metastasis in xenograft models for osteosarcoma, oral cancer, and malignant pleural mesothelioma (MPM) [313–315], supporting clinical assessment of anti-PDPN antibodies in the future. The gene discussed is PDPN; the disease is malignant pleural mesothelioma.